Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Axi-cel in patients with R/R LBCL in complete metabolic response

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a single-center study investigating outcomes of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who were in complete metabolic response before axicabtagene ciloleucel (axi-cel) infusion, compared to those who were not in complete metabolic response. Results showed improved outcomes and a lower adverse event rate for the patients in complete metabolic response prior to CAR-T infusion. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Hutchinson MediPharma: Consultancy; ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; ALX Oncology: Research Funding; Sobi: Research Funding; Roche Genentech: Consultancy.